Transcriptomic analysis of skin fibroblasts in scleroderma
Official title: Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Run by Centre Hospitalier Universitaire Dijon · NCT07256418 · Data updated 2026-11-12
This project will analyze gene activity in skin fibroblasts from people with systemic scleroderma and from surgical controls to see if fibroblasts contribute to the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Status | Recruiting |
| Started | January 26, 2026 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | January 29, 2026 |
| Trial ID | NCT07256418 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with systemic scleroderma who can give written informed consent and have social security coverage are eligible, and control participants are adults undergoing elective plastic or reconstructive surgery without chronic inflammatory or autoimmune skin disease.
✕Probably not a fit
People who are minors, unable to consent, under legal protection measures, or without social security coverage are excluded and would not be eligible to participate or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects skin samples from adults with systemic scleroderma and from control participants undergoing elective plastic or reconstructive surgery. Researchers will isolate cutaneous fibroblasts and perform transcriptomic analyses to compare gene-expression patterns. The team is particularly interested in signatures of fibroblast senescence, immune activation, and pathways linked to fibrosis. Findings aim to clarify fibroblasts' role in disease mechanisms and to highlight candidate biomarkers or targets for future therapies.
Why it matters
Potential benefit: If successful, the work could identify molecular signatures that help guide development of targeted treatments or biomarkers for disease activity.
How similar studies have gone: Previous transcriptomic studies of skin and fibroblasts in scleroderma have identified fibrosis-related gene signatures and pathways, though translating those findings into approved therapies has been limited so far.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: FOR PATIENTS WITH SCLERODERMA : * Person who has given written consent * Person with systemic scleroderma FOR CONTROL PARTICIPANTS : * Person who has given written consent * Person undergoing plastic, cosmetic and reconstructive surgery Exclusion Criteria: FOR PATIENTS WITH SCLERODERMA : * Person not affiliated to or not benefiting from a social security scheme * Person subject to a legal protection measure (curatorship, guardianship) * Person subject to a legal protection measure * An adult who is incapable or unable to give consent * Minors FOR CONTROLLED PARTICIPANTS : * Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases * Person not affiliated to or not benefiting from a social security scheme * Person under legal protection (curatorship, guardianship) * Person subject to a legal protection measure * An adult who is incapable or unable to give consent * Minors
Where it's running
-
CHU Dijon Bourgogne
Dijon, France Recruiting
Study contacts
- Study coordinator: Bernard BONNOTTE
- Email: Bernard.bonnotte@chu-dijon.fr
- Phone: 03.80.29.34.32
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First-in-human test of PRO-203 in healthy adults and people with systemic sclerosis
Researchers will test a single subcutaneous dose of PRO-203 in healthy adults and in people with systemic sclerosis to see if it is safe and how the body handles it.
-
EVM18001 for adults with refractory lupus, myasthenia gravis, and scleroderma
This single-arm study will test an experimental CAR‑T therapy called EVM18001 to see if it is safe and helps adults whose lupus, myasthenia gravis, or scleroderma did not respond to standard treatments.
-
Biopsychosocial (BETY) exercise program for children and adults with scleroderma
This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.
-
Physical performance and daily function in people with scleroderma
This project will test which questionnaires and simple physical tests best measure physical performance and daily functioning in children and adults with scleroderma.
-
Chewing and swallowing performance in people with scleroderma
This project will see how children and adults with scleroderma chew and swallow and collect biopsychosocial information using questionnaires.
-
AlloNK® therapy combined with rituximab for treating certain autoimmune diseases
This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.